Peer-reviewed veterinary case report
New eye drops helping cats with glaucoma not helped by usual treatment
By Ahn, Jaesang & Jeong, Dajeong·Published in Veterinary ophthalmology·2026·Dr. Ahn's Animal Eye Clinic, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The Clinical Efficacy of a Topical Selective EP2 Receptor Agonist Against Feline Glaucoma That Is Not Responsive to Conventional Anti-Glaucoma Eyedrops.
- Species:
- cat
Plain-English summary
A group of 11 cats with glaucoma that didn't respond to regular eye drops were treated with a new topical medication called Omidenepag isopropyl (OMDI). Before starting the treatment, the cats had high eye pressure, averaging 53.6 mmHg, and some had already lost their vision. After using OMDI, four cats maintained their vision long-term, while others showed short-term improvements. This suggests that OMDI could be a helpful option for treating feline glaucoma, especially if started early in the disease.
People also search for: cat glaucoma treatment · feline eye drops for glaucoma · why is my cat's eye watering · cat vision loss glaucoma · OMDI for cats
Abstract
OBJECTIVE: To evaluate the clinical efficacy of the Omidenepag isopropyl 0.002% ophthalmic solution (OMDI) (Eybelis, topical selective EP2 receptor agonist) for feline glaucoma. ANIMAL STUDIED: Eleven client-owned cats. PROCEDURES: The medical records of cats prescribed OMDI between August 2021 and February 2024 were reviewed. These eye drops were administered to feline eyes that were unresponsive to conventional anti-glaucoma medications. Eyes responding to OMDI for ≥ 6, 1-6, and < 1 months were classified as long-term responders, short-term responders, and non-responders, respectively. RESULTS: OMDI was administered BID-QID to 12 eyes of 11 cats diagnosed with various glaucoma etiologies: primary glaucoma and secondary glaucoma (lens-induced uveitis from Morgagnian cataract, aqueous misdirection syndrome, idiopathic anterior uveitis, anterior uveitis from systemic hypertension). The mean intraocular pressure immediately before OMDI administration was 53.6 mmHg (range, 32-86 mmHg). Five eyes retained vision, whereas seven were non-visual. The patients were followed for an average duration of 337.4 days (range, 28-1281 days) after treatment initiation. Four, two, and six eyes were classified as long-term responders, short-term responders, and non-responders, respectively. Four of the five eyes with vision before OMDI administration were classified as long-term responders. Contrastingly, none of the blind eyes without vision before drug administration were classified as long-term responders. CONCLUSION: OMDI could be an additional therapeutic option for feline glaucoma that is unresponsive to conventional therapies. Administration of OMDI following the early diagnosis of glaucoma is recommended to maximize therapeutic efficacy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40714849/